Clinical Trials

  • An all-green glass building facade with a logo that reads "MERCK" is displayed on the exterior of the research facility.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Merck reveals study success, and possible safety worries, for eye drug hopeful

    A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.

    By Kristin Jensen • Sept. 24, 2026
  • An illustration of the kidneys, colored red and blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roche, Ionis RNA drug scores in kidney disease study

    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers. 

    By • Sept. 23, 2026
  • Radiopharmaceutical Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Radiopharmaceuticals

    A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

    By BioPharma Dive staff
  • Shrugs and trees surround a large metal Amgen sign displayed outside a modern office building.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen reports a Phase 3 win with Sjögren’s drug candidate

    Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.

    By • Sept. 22, 2026
  • A picture of tablets and injectable medicines for obesity.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Viking shares surge on updated obesity drug data

    Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote. 

    By • Sept. 22, 2026
  • A micrograph of a mast cell or mastocyte, with smooth muscle fibers stained in blue.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Celldex sinks as safety concerns cloud immune drug results

    Though barzolvolimab displayed what one analyst described as the best efficacy results to date against chronic skin hives, treatment was also associated with two life-threatening anaphylaxis cases.

    By Kristin Jensen • Sept. 22, 2026
  • A close-up of a person's brown eye.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Beacon eye gene therapy hits mark in late-stage study

    Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.

    By • Sept. 21, 2026
  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Xenon shares fall following depression trial pause

    The occurrence of “neuropsychiatric” adverse events in testing fueled investor doubts about a drug the FDA is already reviewing for a form of epilepsy.

    By • Sept. 18, 2026
  • An illustration of neuron cells in abstract dark space.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Skyhawk racks up more support for Huntington’s drug

    The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.

    By • Sept. 16, 2026
  • An illustration of a cancerous tumor inside the lungs
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight

    The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.

    By , • Sept. 15, 2026
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

    As dueling data emerge between their drug ivonescimab and a rival Merck medication, Summit and Akeso revealed new findings that impressed Wall Street.

    By • Sept. 14, 2026
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca’s newly approved pill fails frontline breast cancer study

    Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year. 

    By • Sept. 14, 2026
  • A stylized illustration of the human urinary system with the bladder highlighted.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tyra disappoints investors with bladder cancer data

    Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.

    By • Sept. 9, 2026
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    Novartis RNA drug falls short in rare muscle disease study

    The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s business development acumen, according to one analyst.

    By • Sept. 8, 2026
  • A stethoscope rests on top of an EKG printout. A cool blue cast dominates the scene.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines

    Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.

    By • Sept. 5, 2026
  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Trailing rivals, AbbVie scores win with dual-acting myeloma drug

    The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

    By • Sept. 4, 2026
  • An Ultragenyx sign is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Ultragenyx
    Image attribution tooltip

    Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study

    The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat disease and is forcing Ultragenyx to closely examine its expenses.

    By Kristin Jensen • Sept. 3, 2026
  • An illustration of two immune checkpoint proteins binding
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Akeso, Summit cancer drug confirms lung cancer survival benefit

    A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.

    By • Sept. 3, 2026
  • A sign spelling Novartis hangs on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Novartis says MS pill succeeds in two large studies

    Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.

    By • Sept. 1, 2026
  • A falling line on a stock chart.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Alumis’ TYK2 drug fails in key lupus study

    Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis. 

    By • Sept. 1, 2026
  • An anatomical model of the heart sits on a desk in a doctor's office
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy

    At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

    By • Aug. 31, 2026
  • Heart
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease

    Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.

    By • Aug. 28, 2026
  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    New data could widen use of AstraZeneca, Amgen immune disease drug

    Tezspire succeeded in a study in eosinophilic esophagitis, which could become the drug’s third approved indication and unlock what’s viewed as a blockbuster opportunity.

    By • Aug. 27, 2026
  • An illustration of antibodies attacking a nerve cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Spyre tumbles as immune drug misses mark in rheumatoid arthritis

    The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A protein might be against the condition.

    By • Aug. 26, 2026
  • Promotional graphic for Season 2 of The Progress Profile: Alzheimer’s Research in Focus, featuring the Pearson and BioPharma Dive logos on a dark blue background with abstract glowing blue wave patterns on the right.
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

    This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

    By BioPharma Dive's studioID • Aug. 24, 2026
  • A picture of a Moderna building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Vaccines

    Cancer vaccine win restores Wall Street’s faith in Moderna

    Moderna gained $45 billion in market value in a single day, a surge that brought the company’s stock to levels not seen since 2024 — and saddled it with expectations that may be tough to meet. 

    By , • Aug. 20, 2026